Moderna· @moderna_tx · X·· 2026-07-16AI 评分32
AI 导读
今天，我们宣布在我们评估mRNA-4200的一期研究中，首位美国受试者已完成给药。mRNA-4200是一款肿瘤靶向癌症抗原疗法候选药物，用于晚期或转移性实体瘤患者。 阅读更多：https://feeds.issuerdirect.com/news-release.html?newsid=6014596879866592&symbol=MRNA
正文
Today we announced the dosing of the first U.S. participant in our Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors.
Read more: https://feeds.issuerdirect.com/news-release.html?newsid=6014596879866592&symbol=MRNA
来源：Moderna · x.com